Regeneron Pharmaceuticals makes medicines that patients take repeatedly, often for the rest of their lives. Its biggest earners are Dupixent, which treats severe skin conditions, asthma, and other inflammatory diseases, and the EYLEA family of eye injections, which prevent blindness in people with serious retinal diseases. Patients do not take these drugs once and stop. They come back for refills, for injections every few weeks, for prescriptions renewed year after year. That repeat-purchase pattern is what turns a single approval from regulators into a long-running revenue stream. The diagram below traces where the money goes.

Five years of financial data tell a story with two distinct chapters. In 2021, revenue surged to $16.1 billion, nearly double the prior year, powered in large part by COVID-19 antibody treatments funded by the U.S. government. That spike was temporary. When COVID-19 treatments stopped selling, revenue fell to $12.2 billion in 2022. Then the underlying business took over. Dupixent kept growing, new indications were approved, and revenue climbed back: $13.1 billion in 2023, $14.2 billion in 2024, and $14.3 billion in 2025. Strip out the pandemic distortion and what remains is a company that has been growing steadily through its core medicines.

The profitability of this business is remarkably consistent. Gross margin, meaning what is left after the direct cost of making the drugs, has stayed between 85% and 87% every year from 2021 through 2025. That means for every dollar of revenue, roughly 85 to 87 cents remains before paying for research, sales, and administration. Free cash flow, the actual cash left over after all spending including capital investment, was $7.1 billion in 2021, dropped with revenue to $5.0 billion in 2022, and has held in a range of $4.4 billion to $5.0 billion since. The company carries more cash and marketable securities than debt, with net debt of negative $1.1 billion at the end of 2025, meaning it has more money saved than it owes.

Dupixent is the engine underneath all of this. Global net product sales of Dupixent reached $17.8 billion in 2025, up from $14.1 billion in 2024 and $11.6 billion in 2023. Regeneron does not record those sales directly. Sanofi, its partner, books the revenue. Regeneron instead receives a share of the profits. In 2025, that share came to $5.2 billion from Sanofi, making it the single largest line in Regeneron's income. This structure means Regeneron's reported revenue understates how much economic value Dupixent actually generates for the company.

The most concrete threat to the current revenue picture is what is happening to EYLEA. Biosimilar versions of EYLEA entered the U.S. market, and U.S. net product sales of EYLEA fell from $4.8 billion in 2024 to $2.7 billion in 2025, a drop of more than 40%. Regeneron launched a newer, higher-dose version called EYLEA HD to help offset this, and U.S. sales of EYLEA HD grew from $1.2 billion in 2024 to $1.6 billion in 2025. But EYLEA HD has not yet fully replaced what EYLEA is losing. More biosimilar versions of EYLEA are expected to launch in the second half of 2026, which the company's own filings say will continue to put pressure on both products.

A second risk sits above all others in terms of scale. Regeneron's two biggest products together, EYLEA HD plus EYLEA at 31% of total revenue, and the Dupixent profit share at 41% of total revenue, account for roughly 72% of what the company takes in. If either product stumbles, whether from competition, a safety finding, a change in insurance coverage, or a government decision to force lower prices, the financial impact would be severe. The company received a letter from the President in July 2025 asking it to provide drugs at lower prices within 60 days. Federal programs that negotiate drug prices and require companies to match prices in other countries are described in the company's own risk disclosures as a serious threat to profits.

Regeneron is not standing still. Research and development spending rose from $4.4 billion in 2023 to $5.1 billion in 2024 and $5.9 billion in 2025. The company has roughly 45 product candidates in clinical development, spanning cancer, rare diseases, blood disorders, and neurological conditions. Recent approvals include Lynozyfic for multiple myeloma and Ordspono for certain lymphomas. Pipeline programs testing treatments for FOP, myasthenia gravis, blood clotting disorders, and hereditary hearing loss are approaching regulatory decisions in 2026. The company is also studying a weight-related treatment called trevogrumab in combination with semaglutide.

Manufacturing adds another layer of risk. Regeneron relies on a limited number of facilities in New York and Ireland, plus outside manufacturers. In 2025, an FDA inspection at an outside manufacturing site called Catalent Indiana delayed approvals for EYLEA HD in a pre-filled syringe format and for a blood cancer drug called Ordspono. The company resubmitted those applications using a different manufacturer. Delays like this do not necessarily become permanent problems, but they push revenue timelines out and add uncertainty to launch plans.